The company reported that its 2015 annual sales totaled 27.8 million euros, up significantly from the 24.2 million recorded in 2014. Executives said foreign exchange rates boosted proceeds 10 percent. Medicrea earned a record 14 million euros during the second half of last year, a 14 percent increase compared with the 12.3 million euros garnered during the final six months of 2014, according to the firm.
"We are beginning to reap the benefits of the commercial investments carried out in 2014 that led to the opening of new export markets in 2015, essentially in Eastern Europe and South America. This trend is likely to continue in 2016 thanks to the signing of new distribution agreements in Asia and the Middle East, the creation of our German subsidiary and the implementation of a new marketing organization in our British entity," said Denys Sournac, chairman/CEO of Medicrea. "We are making headway in France, where surgeons’ interest in our innovations and our UNiD customized implant platform enabled us to generate a 23 percent increase in sales compared with the previous year. We are continuing to invest heavily in our priority market in the United States, which accounted for 60 percent of total sales over the last year, in order to expand our sales force and directly promote our customized implants among patients.”
The Medicrea Group specializes in the design, manufacture, and distribution of proprietary spinal surgery technologies. The Group’s headquarters are based near Lyon, France; it also has an implant and surgical instrument manufacturing facility in La Rochelle, France, as well as four distribution subsidiaries in the United States, the United Kingdom, France and Germany.